Table 3. Summary of the meta-analysis of thromboprophylaxis safety following CS.
| subgroup | Included studies | N | Bleeding/ haematomas | N | Blood transfusion | N | Wound complications | N | Allergic reactions | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RR (95% CI) | I2 | P(%) | RR (95% CI) | I2 | P(%) | RR (95% CI) | I2 | P(%) | RR (95% CI) | I2 | P(%) | |||||||
| LMWH versus negative control | overall | 4 | 8.47 (1.52–47.11) | 0 | 0.01 | 3 | 2.48(0.04–146) | 73 | 0.66 | 3 | 2.42(0.71–8. 24) | 0 | 0.16 | 3 | NE | NA | NA | |
| RCTs | 3 | 6.17(0.76–49.96) | NA | 0.09 | 2 | 0.32(0.01–7.54) | NA | 0.48 | 2 | 1.94(0.50–7.44) | 0 | 0.34 | 3 | NE | NA | NA | ||
| Cohort | 1 | 11.89(0.70–200.7) | NA | 0.09 | 1 | 17.07(1.03–282) | NA | 0.05 | 1 | 4.65(0.25–85.97) | NA | 0.30 | 0 | — | — | — | ||
| Unknown risk of VTE | 4 | 8.47 (1.52–47.11) | 0 | 0.01 | 3 | 2.48(0.04–146) | 73 | 0.66 | 3 | 2.42(0.71–8. 24) | 0 | 0.16 | 3 | NE | NA | NA | ||
| LMWH versus UFH | overall | 2 | NE | NA | NA | 0 | — | — | — | 0 | — | — | — | 1 | NE | NA | NA | |
| RCTs | 2 | NE | NA | NA | 0 | — | — | — | 0 | — | — | — | 1 | NE | NA | NA | ||
| Unknown risk of VTE | 1 | NE | NA | NA | 0 | — | — | — | 0 | — | — | — | 1 | NE | NA | NA | ||
| high risk of VTE | 1 | NE | NA | NA | 0 | — | — | — | 0 | — | — | — | 0 | — | — | — | ||
| LMWH versus LMWH | overall | 3 | NE | NA | NA | 0 | — | — | — | 0 | — | — | — | 2 | NE | NA | NA | |
| RCTs | 3 | NE | NA | NA | 0 | — | — | — | 0 | — | — | — | 2 | NE | NA | NA | ||
| high risk of VTE | 3 | NE | NA | NA | 0 | — | — | — | 0 | — | — | — | 2 | NE | NA | NA | ||
Abbreviations: N, number of studies; OR, odds ratio; CI, confidence interval; P, P value for association; NE, not estimable; NA, not applicable